



Contact
Deborah MacDonnell
Sullivan & LeShane Public Relations
860-560-0001, cell: 860-214-1631

FOR IMMEDIATE RELEASE
JUNE 7, 2004

NEW ERA OF HEALTHCARE OPENING TO PUBLIC THROUGH HARTFORD HOSPITAL AND GENOMAS

Partnership ushers into city a new center for personalized medicine

HARTFORD – Gualberto Ruaño, M.D., Ph.D., a Connecticut-based physician scientist and entrepreneur in genomic medicine, and Hartford Hospital today announced a partnership that establishes the Hartford Hospital Genetics Research Center with Dr. Ruaño’s company, Genomas, as the biotechnology anchor. It is a quantum step forward that opens doors to a new era of personalized medicine for people in the Hartford community and throughout Connecticut.

“With Genomas, we are taking a personalized approach, using it to guide treatment – not telling the patient what the problem is, but rather, how we can prevent and treat metabolic disorders,” said Dr. Ruaño. “And with Hartford Hospital’s 150-year history of the best in clinical care, we’re not only catapulting the city into the fast lane for leading edge personalized healthcare, we’re also continuing that positive legacy of caring for patients.”

The partnership is expected to be made official today with a ribbon-cutting ceremony from 4 to 5:30 p.m. Hospital officials and medical staff will join Dr. Ruaño and the Genomas staff at Hartford Hospital’s Crane Building on Jefferson Street where the hospital’s new Genetics Research Center and Genomas are located. Guests can tour the facility to see for themselves how it will be used in this exciting new venture.

“There is great symbolism in the fact that Hartford Hospital is converting one of its oldest buildings into a high-tech launching pad for the new era of personalized medicine,” said Hartford Hospital Chief Executive Officer John Meehan. “Taking this important step in the year of our 150th anniversary makes it even more meaningful to all of us within the hospital community.”

The hospital’s Genetics Research Center will translate the daily practice of the best medicine at Hartford Hospital into the most modern imaging possible, unique views of the inherited constitution of each individual as she or he responds to treatments. By learning from today’s patient care, and using this knowledge to predict the best treatments for the future, Hartford Hospital now catapults its mission into the next 150 years, Meehan said.

--more--

**Hartford Hospital partners with Genomas
To launch new era of personalized medicine
Page 2**

The partnership opens a totally new area of science to society, encouraging news for Connecticut business that could mean tremendous growth in an industry new to most people. “Conventionally people perceive genomics to be part of drug discovery and a purely scientific endeavor. Now it is poised to transition into other industries critical to Connecticut, such as healthcare services and disease management,” Dr. Ruaño said. “It is a meaningful strategy for preventing and/or treating disease moving forward.”

Genomas’ product development focus is metabolic syndrome and associated disorders, including obesity and diabetes. Metabolic syndrome is a serious disorder diagnosed by central obesity, imbalances in lipids, elevated blood pressure and glucose intolerance. It is the predecessor to the dire consequences of diabetes, cardiovascular disease and end-stage organ damage. The Centers for Disease Control estimates that 40 percent of the adult population in the United States has metabolic syndrome. Prevention of metabolic syndrome and diabetes has become a major public health imperative.

Genomas, through its proprietary PhysioType™ products, provides the physician with customized and evidence-based clinical programs of diet, exercise and drugs for each patient in treating or preventing obesity, metabolic syndrome and diabetes. These programs are superior to existing empirical modes of nutritional and exercise counseling and drug treatment based. The use of PhysioTypes should result in optimized healthcare, fewer physicians and hospital visits, reduced use of prescription drugs with their occasional side effects and enhanced health. Genomas will conduct clinical studies in partnership with Hartford Hospital and other medical centers to produce these PhysioTypes. Physicians will use the product to recommend precise and personalized treatments

Gualberto Ruaño founded Genomas in September 2003 and serves as President and CEO. Dr. Ruaño has 15 years of experience in biotechnology, having founded two other companies prior to Genomas. With M.D. and Ph.D. degrees from Yale University, Dr. Ruaño has been an advocate of personalized healthcare for 10 years, and is one of the visionaries in the field. In addition to the partnership with Hartford Hospital, Genomas has research collaborations with faculty at the University of Connecticut (diet and nutrition), Children’s National Medical Center (systems physiology) and Yale University School of Medicine (biostatics).

ABOUT GENOMAS

Genomas is developing novel diagnostic products to personalize disease prevention and health enhancement. The company’s proprietary physiogenomics technology allows it to rapidly and precisely produce PhysioType™ products. PhysioTypes are predictors of response to diet, exercise and drugs, not diagnostics for disease, and are utilized to direct preventive strategies. A PhysioType product is made from the combination of all genetic, physiological or clinical markers that Genomas has discovered to be significant determinants of individual response. PhysioTypes are revolutionary healthcare products, which empower physicians with the unprecedented capability to prescribe personalized and highly effective preventive treatments incorporating diet, exercise and drug regimens for each patient. Genomas conducts clinical research with major clinical institutions to discover these PhysioTypes and commercializes them to practicing physicians and hospitals. *For more information please access the company’s web site at www.genomas.net*